

Anilkumar Pillai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2811256/publications.pdf>

Version: 2024-02-01

46
papers

1,567
citations

361413

20
h-index

302126

39
g-index

48
all docs

48
docs citations

48
times ranked

2562
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 535.	2.1	232
2	Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. <i>Journal of Psychiatric Research</i> , 2007, 41, 372-386.	3.1	128
3	Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. <i>Schizophrenia Research</i> , 2006, 82, 95-106.	2.0	121
4	Brain-Derived Neurotrophic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of Schizophrenia. <i>NeuroSignals</i> , 2008, 16, 183-193.	0.9	113
5	Dysregulation of estrogen receptor beta (ER β), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects. <i>Molecular Autism</i> , 2014, 5, 46.	4.9	90
6	Plasma BDNF Levels Vary in Relation to Body Weight in Females. <i>PLoS ONE</i> , 2012, 7, e39358.	2.5	76
7	Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 246-256.	4.1	62
8	Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 48-58.	2.5	57
9	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. <i>Schizophrenia Research</i> , 2014, 157, 84-89.	2.0	50
10	Ubiquitin-proteasome dependent degradation of GABA β 1 in autism spectrum disorder. <i>Molecular Autism</i> , 2014, 5, 45.	4.9	42
11	Altered mRNA Levels of Glucocorticoid Receptor, Mineralocorticoid Receptor, and Co-Chaperones (FKBP5 and PTGES3) in the Middle Frontal Gyrus of Autism Spectrum Disorder Subjects. <i>Molecular Neurobiology</i> , 2016, 53, 2090-2099.	4.0	42
12	Complement C3 Expression Is Decreased in Autism Spectrum Disorder Subjects and Contributes to Behavioral Deficits in Rodents. <i>Molecular Neuropsychiatry</i> , 2017, 3, 19-27.	2.9	42
13	Erythropoietin Prevents Haloperidol Treatment-Induced Neuronal Apoptosis through Regulation of BDNF. <i>Neuropsychopharmacology</i> , 2008, 33, 1942-1951.	5.4	41
14	Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. <i>Schizophrenia Research</i> , 2006, 87, 48-59.	2.0	35
15	Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex. <i>Journal of Neurochemistry</i> , 2008, 107, 941-951.	3.9	31
16	Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: A gene–environment interaction study. <i>European Neuropsychopharmacology</i> , 2014, 24, 1324-1336.	0.7	30
17	Altered Expression of Endoplasmic Reticulum Stress-Related Genes in the Middle Frontal Cortex of Subjects with Autism Spectrum Disorder. <i>Molecular Neuropsychiatry</i> , 2017, 3, 85-91.	2.9	30
18	Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. <i>Psychiatric Clinics of North America</i> , 2012, 35, 645-659.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Decreased Expression of Sprouty2 in the Dorsolateral Prefrontal Cortex in Schizophrenia and Bipolar Disorder: A Correlation with BDNF Expression. PLoS ONE, 2008, 3, e1784.	2.5	27
20	Mitophagy in depression: Pathophysiology and treatment targets. Mitochondrion, 2021, 61, 1-10.	3.4	23
21	Inflammatory Pathways in Psychiatric Disorders: the Case of Schizophrenia and Depression. Current Behavioral Neuroscience Reports, 2020, 7, 128-138.	1.3	22
22	Glucocorticoid regulates TrkB protein levels via c-Cbl dependent ubiquitination: A decrease in c-Cbl mRNA in the prefrontal cortex of suicide subjects. Psychoneuroendocrinology, 2014, 45, 108-118.	2.7	21
23	Neogenin in Amygdala for Neuronal Activity and Information Processing. Journal of Neuroscience, 2018, 38, 9600-9613.	3.6	21
24	Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway. Molecular Psychiatry, 2021, 26, 3043-3059.	7.9	21
25	Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophrenia Research, 2018, 193, 263-268.	2.0	18
26	Long-Term Effects of Prenatal Hypoxia on Schizophrenia-Like Phenotype in Heterozygous Reeler Mice. Molecular Neurobiology, 2016, 53, 3267-3276.	4.0	17
27	Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia. Current Behavioral Neuroscience Reports, 2019, 6, 37-50.	1.3	15
28	Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum. Journal of Neurochemistry, 2006, 98, 1411-1422.	3.9	13
29	Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia. Current Neuropharmacology, 2014, 12, 100-107.	2.9	13
30	Plasma BDNF levels following weight recovery in anorexia nervosa. Physiology and Behavior, 2016, 165, 300-303.	2.1	12
31	Estrogen Receptor $\hat{1}^2$ Agonist Attenuates Endoplasmic Reticulum Stress-Induced Changes in Social Behavior and Brain Connectivity in Mice. Molecular Neurobiology, 2018, 55, 7606-7618.	4.0	12
32	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry, 2019, 1, 100007.	1.0	10
33	A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels. Neuropsychobiology, 2021, 80, 411-424.	1.9	10
34	Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement. Psychiatry Research, 2020, 291, 113285.	3.3	9
35	Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats. Pharmacology Biochemistry and Behavior, 2020, 189, 172853.	2.9	9
36	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. Journal of Affective Disorders, 2021, 286, 275-281.	4.1	9

#	ARTICLE	IF	CITATIONS
37	A randomized controlled trial of exercise on augmenting the effects of cognitive remediation in persons with severe mental illness. <i>Journal of Psychiatric Research</i> , 2021, 139, 38-46.	3.1	9
38	Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 21, 100441.	2.5	7
39	Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. <i>Journal of Geriatric Care and Research</i> , 2018, 5, 57-67.	1.0	4
40	Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia. <i>Schizophrenia Research</i> , 2014, 158, 268-269.	2.0	3
41	Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 197, 172999.	2.9	3
42	Clq deletion exacerbates stress-induced learned helplessness behavior and induces neuroinflammation in mice. <i>Translational Psychiatry</i> , 2022, 12, 50.	4.8	3
43	Transglutaminase 2 Induces Deficits in Social Behavior in Mice. <i>Neural Plasticity</i> , 2018, 2018, 1-9.	2.2	2
44	The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 154-164.	1.3	1
45	T115. TARGETING NICOTINIC AND NMDA RECEPTORS CONCURRENTLY: ROCKET SCIENCE, COMMON SENSE OR GAME CHANGER?. <i>Schizophrenia Bulletin</i> , 2019, 45, S248-S248.	4.3	1
46	Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD. <i>Heliyon</i> , 2019, 5, e01709.	3.2	1